Improved margins, strong cash flow, and revised full-year guidance reflect momentum in core operations in Q2 for HCA Healthcare

Overview

HCA Healthcare reported strong second-quarter 2025 results, with top-line growth supported by higher patient volumes and favorable payer mix. The company also demonstrated improved profitability and operating leverage, leading to a full-year guidance revision. Strong cash flow performance and continued investment in facilities and technology underscored HCA’s operational discipline and long-term growth outlook.

“We are pleased to report strong financial results for the second quarter. They reflected solid revenue growth, improved margins, and better outcomes for our patients. I want to thank our exceptional colleagues for their great work and continuous efforts to improve”, said Sam Hazen, Chief Executive Officer of HCA Healthcare.

Q2 2025 vs. Q2 2024:

• Revenue reached to $18.61bn (+6.4% YoY), driven by growth in admissions, emergency room visits, and outpatient services.
• Net income attributable to HCA Healthcare increased to $1.65bn (compared to $1.46 billion in Q2 2024), a +13.1% increase YoY.
• Diluted earnings per share (EPS) rose to $6.83 (+23.5% YoY from $5.53), benefiting from operating margin improvement and share repurchases. Adjusted EPS was $6.84 (+24.4% YoY versus Q2 2024).
• Adjusted EBITDA totaled $3.85bn (up from $3.55bn), reflecting an 8.4% YoY gain.
• Same facility admissions increased 1.8%, and equivalent admissions were up 1.7%, with ER visits growing 1.3%.
• Inpatient surgeries declined 0.3%, and outpatient surgeries decreased 0.6%, partially offset by growth in procedural mix.
• Operating cash flow was $4.21bn, a significant increase from $1.97bn in Q2 2024, supported by earnings growth and working capital efficiency.
• The company repurchased 7.03m shares during the quarter for $2.51bn, continuing its balanced capital allocation strategy.

Following strong first-half performance, HCA raised its full-year 2025 guidance across key metrics. Revenue is now expected between $74.0bn and $76.0bn, up from the previous range of $72.8bn-$75.8bn. Net income attributable to HCA is projected between $6.11bn and $6.48bn, revised upward from $5.85bn-$6.29bn. Adjusted EBITDA is forecasted in the range of $14.70bn to $15.30bn, compared to the prior outlook of $14.30bn-$15.10bn. Diluted EPS is now guided between $25.50 and $27.00, increased from $24.05-$25.85 previously, reflecting stronger margins and capital return activity. Capital expenditures for 2025 remain estimated at approximately $5.0bn, consistent with prior guidance.

HCA shares are currently trading below both the 50-day SMA ($373.66) and the 200-day SMA ($344.92), indicating a bearish short-term outlook. The stock has recently broken below the 200-day moving average, a critical support level, suggesting weakening momentum. The RSI (14) sits at 31.03, just above the oversold threshold of 30, which may imply that downside pressure is losing steam, although not yet signaling a confirmed reversal. The overall setup reflects a correction phase, with potential for technical rebound if support near $330 holds, but confirmation above the 200-day SMA is needed to shift sentiment back to neutral or bullish.

Author: Andreea-Roxana Danci